Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hematologic Diseases × CHR 2845 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Diseases 1

Interventions

Brentuximab Vedotin 17 Rituximab 8 pirtobrutinib 7 dacetuzumab 6 ruxolitinib 5 Lenalidomide 5 Doxorubicin 5 Cyclophosphamide 5 ponatinib 4 Vincristine 4 Prednisone 4 Imatinib Mesylate 4 Azacitidine 4 nilotinib 3 lintuzumab 3 Bortezomib 3 Bendamustine Hydrochloride 3 vosaroxin 2 venetoclax 2 spartalizumab 2 ibrutinib 2 KW-2478 2 Ifosfamide 2 Etoposide 2 Dexamethasone 2 Cytarabine 2 Carboplatin 2 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2 zanubrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00820508 2011-11-28

CHR-2845-001

Chroma Therapeutics

Phase 1 Completed

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡